Aeterna Zentaris (NASDAQ:AEZS) coverage started on

Stock research analysts at began reporting on shares of Aeterna Zentaris (NASDAQ:AEZS – Get a Free Report) (TSE:AEZ) in a research note issued Monday. The company issued a sell rating on the biopharmaceutical company’s shares.

Aeterna Zentaris Price Performance

Aeterna Zentaris shares opened at $1.95 on Monday. Aeterna Zentaris has a one-year low of $1.36 and a one-year high of $3.38. The company has a market cap of $9.48 million, a price-to-earnings ratio of -0.57 and a beta of 1.57. The stock’s 50-day moving average price is $1.97 and its 200-day moving average price is $1.89.

Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last published its quarterly results on Wednesday, March 27. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) ($0.19). Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%. The company had revenue of $0.12 million during the quarter.

Company profile of Aeterna Zentaris

(Get a free report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in the development and commercialization of therapies and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates growth hormone secretion by binding to the GHSR-1a for the diagnosis of growth hormone deficiency in adults and growth hormone deficiency in adults. , as well as oncological indications; and AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical development for the treatment of hypoparathyroidism in adults.

Recommended articles

Get daily news and reviews for Aeterna Zentaris – Enter your email address below to receive a daily summary of the latest news and analyst ratings for Aeterna Zentaris and related companies with’s FREE daily email newsletter.